Helius Medical Technologies, INC.: insider trades · United States · SEC (Form 4)

About Helius Medical Technologies, INC.

HELIUS MEDICAL TECHNOLOGIES, INC. (ticker: HSDT) is a U.S.-listed company that has traded on the NASDAQ market in the United States. Historically, Helius was a highly specialized neurotechnology and medical-device company focused on non-implantable neuromodulation solutions designed to help patients with neurological deficits, especially balance and gait impairments. Its principal executive offices are in Newtown, Pennsylvania, United States, which underscores its U.S. operating base and its identity as a niche medical technology name rather than a diversified healthcare platform. The company’s roots go back to 2014, when it completed the acquisition of NeuroHabilitation Corporation and adopted the Helius Medical Technologies name to reflect its new strategic direction. Over time, Helius built its business around a single lead platform: the Portable Neuromodulation Stimulator, or PoNS. PoNS is a wearable device consisting of a controller and a mouthpiece that delivers mild electrical stimulation to the tongue. The therapeutic premise is to enhance neuroplasticity and support rehabilitation exercises, with the goal of improving gait and balance in patients with certain neurological conditions. In practical terms, Helius’ core business has centered on PoNS Therapy and on navigating the clinical, reimbursement, and regulatory pathways required to turn a novel neurostimulation concept into a commercially viable product. Its commercial focus has been on patients with multiple sclerosis and on balance deficits associated with mild to moderate traumatic brain injury. The company’s competitive position is therefore that of a small, differentiated medtech innovator: it is not a broad device manufacturer, but a focused developer whose upside depends on clinical adoption, payer coverage, and regulatory progress. Geographically, Helius has primarily targeted the United States, while also seeking international traction in markets such as Canada and other jurisdictions where device authorization or reimbursement could broaden the addressable opportunity. For investors in French-speaking Europe, the name should be viewed as a small-cap healthcare story with substantial execution risk and potentially high sensitivity to reimbursement developments, commercialization milestones, and balance-sheet management. Recent developments have been especially important. In 2025, the company reported financing activity, updates on its commercial and reimbursement strategy, and continued work on its PoNS program. SEC filings also show a major corporate pivot: in September 2025, Helius changed its corporate name to Solana Company, signaling a strategic transition away from the original medtech identity. Even so, the legacy Helius franchise remains defined by its neurotechnology origins, its PoNS platform, and its attempt to build a clinically meaningful, non-invasive therapy for neurological rehabilitation.